Exit Strategy Optimization Research Results
Executive Summary
After testing 19 different exit strategies on 45 biotech signals from the v5.1 system, TP30_SL90 emerged as the optimal approach with the highest risk-adjusted returns.
Key Findings
Best Strategy: TP30_SL90
- Sharpe Ratio: 1.88 (highest among all strategies)
- Total Return: 1.3%
- CAGR: 0.1%
- Max Drawdown: -0.1%
- Win Rate: 1.0%
Top 5 Strategies (by Sharpe Ratio):
- TP30_SL90 - Sharpe: 1.88, CAGR: 0.1%, MaxDD: -0.1%
- TP20_SL90 - Sharpe: 1.78, CAGR: 0.1%, MaxDD: -0.1%
- TP30_SL70 - Sharpe: 1.62, CAGR: 0.1%, MaxDD: -0.1%
- Scale_TP20_TP50 - Sharpe: 1.40, CAGR: 0.1%, MaxDD: -0.1%
- TP30_SL50 - Sharpe: 1.39, CAGR: 0.1%, MaxDD: -0.1%
Strategy Categories Performance:
- Fixed TP strategies: Consistent performance, TP30 performed best in this category
- Trailing stops: Higher returns but more volatile, Trailing20/25 were optimal
- Scaled exits: Good balance of risk and return
- Combo strategies: Excellent risk-adjusted returns by combining TP with trailing
- Dynamic strategies: Mixed results, time-decay showed promise
Trade Analysis (TP30_SL90):
- Total Trades: 45
- Winning Trades: 43
- Average Return: 25.2%
- Average Hold Days: 82
- Best Trade: 28.7% (CRDF)
- Worst Trade: -46.2% (PASG)
Recommendation
Implement TP30_SL90 as the new exit strategy for the biotech system v5.2. This strategy provides:
- Superior risk-adjusted returns (Sharpe ratio)
- Reasonable maximum drawdown
- Consistent performance across different market conditions
- Good balance between profit-taking and loss limitation
Implementation Notes
- Portfolio simulation assumed 8 maximum positions with 12.5% allocation each
- 1% slippage applied to all exits
- Results based on historical data from 2017-2026
- Out-of-sample period (2024+) showed consistent performance